Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Fexofenadine | |
| Synonyms |
|
|
| Definitions |
A second generation, long-lasting selective histamine H1 receptor antagonist with antiinflammatory property. Fexofenadine is a highly selective and reversible competitor at peripheral H1 histamine receptors in the gastrointestinal (GI) tract, blood vessels, and bronchial smooth muscle. This agent interferes with mediators release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition fexofenadine may also inhibit the late-phase allergic reaction by acting on leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Overall, this agent blocks the actions of endogenous histamine, thereby leads to temporary relief of the negative symptoms associated with histamine and achieve effects such as decreased vascular permeability, reduction of pruritus and localized smooth muscle relaxation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C61764 |
|
| ALT_DEFINITION |
A drug used to treat certain allergy symptoms. It blocks a chemical released during an allergic response that causes itching, sneezing, runny nose, wheezing, and watery eyes. It is a type of antihistamine.
|
|
| CAS_Registry |
83799-24-0
|
|
| CHEBI_ID |
CHEBI:5050
|
|
| Chemical_Formula |
C32H39NO4
|
|
| code |
C61764
|
|
| Contributing_Source |
FDA
|
|
| definition |
A second generation, long-lasting selective histamine H1 receptor antagonist with antiinflammatory property. Fexofenadine is a highly selective and reversible competitor at peripheral H1 histamine receptors in the gastrointestinal (GI) tract, blood vessels, and bronchial smooth muscle. This agent interferes with mediators release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition fexofenadine may also inhibit the late-phase allergic reaction by acting on leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Overall, this agent blocks the actions of endogenous histamine, thereby leads to temporary relief of the negative symptoms associated with histamine and achieve effects such as decreased vascular permeability, reduction of pruritus and localized smooth muscle relaxation.
|
|
| FDA_UNII_Code |
E6582LOH6V
|
|
| Has_Salt_Form | ||
| in_subset | ||
| label |
Fexofenadine
|
|
| Legacy Concept Name |
Fexofenadine
|
|
| Preferred_Name |
Fexofenadine
|
|
| prefixIRI |
NCIT:C61764
|
|
| prefLabel |
Fexofenadine
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0296800
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |